ReviewExpert opinion on emerging drugs2009
Atrial-selective sodium channel block for the treatment of atrial fibrillation.
Review in Expert opinion on emerging drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Plant-derived compounds as potential candidates for atrial fibrillation drug discovery: A review on phytochemicals with atrial-selective activity.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Review
- Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Article
- The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity.Journal of cardiovascular pharmacology · 2020Article
- Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation.Journal of cardiovascular pharmacology · 2020Review
- Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms.Frontiers in pharmacology · 2020Review
- Mechanisms underlying atrial-selective block of sodium channels by Wenxin Keli: Experimental and theoretical analysis.International journal of cardiology · 2016Article
- Atrial selectivity of antiarrhythmic drugs.The Journal of physiology · 2013Review
- Role of late sodium channel current block in the management of atrial fibrillation.Cardiovascular drugs and therapy · 2013Review
- Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine.Frontiers in pharmacology · 2013Article
- Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.Journal of cardiovascular pharmacology · 2012Article
- Rate-dependent effects of vernakalant in the isolated non-remodeled canine left atria are primarily due to block of the sodium channel: comparison with ranolazine and dl-sotalol.Circulation. Arrhythmia and electrophysiology · 2012Article
- Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.The Journal of pharmacology and experimental therapeutics · 2012Article
- Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.Heart rhythm · 2012Article
- Novel pharmacological targets for the rhythm control management of atrial fibrillation.Pharmacology & therapeutics · 2011Review
- Role of RBM25/LUC7L3 in abnormal cardiac sodium channel splicing regulation in human heart failure.Circulation · 2011Article
- Electrophysiologic basis for the antiarrhythmic actions of ranolazine.Heart rhythm · 2011Review
- Effect of dronedarone on Na+, Ca2+ and HCN channels.Naunyn-Schmiedeberg's archives of pharmacology · 2011Article
- Advances in the Pharmacologic Management of Atrial Fibrillation.Cardiac electrophysiology clinics · 2011Article
- Atrial-selective drugs for treatment of atrial fibrillation.Herzschrittmachertherapie & Elektrophysiologie · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The pharmacological approach to therapy of atrial fibrillation (AF) is often associated with adverse effects resulting in the development of ventricular arrhythmias. As a consequence, much of the focus in recent years has been on development of atrial-selective agents. Atrial-selective sodium channel blockers have recently been shown to exist and be useful in the management of AF. This review summarizes the available data relative to current therapies, focusing on our understanding of the actions of atrial selective sodium channel blockers in suppressing and preventing the induction of AF and electrophysiological properties that confer atrial-selectivity to these antifibrillatory drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.